146 related articles for article (PubMed ID: 12176090)
1. Human variability in polymorphic CYP2D6 metabolism: is the kinetic default uncertainty factor adequate?
Dorne JL; Walton K; Slob W; Renwick AG
Food Chem Toxicol; 2002 Nov; 40(11):1633-56. PubMed ID: 12176090
[TBL] [Abstract][Full Text] [Related]
2. Polymorphic CYP2C19 and N-acetylation: human variability in kinetics and pathway-related uncertainty factors.
Dorne JL; Walton K; Renwick AG
Food Chem Toxicol; 2003 Feb; 41(2):225-45. PubMed ID: 12480299
[TBL] [Abstract][Full Text] [Related]
3. Comparison of pharmacokinetic variability of fesoterodine vs. tolterodine extended release in cytochrome P450 2D6 extensive and poor metabolizers.
Malhotra B; Darsey E; Crownover P; Fang J; Glue P
Br J Clin Pharmacol; 2011 Aug; 72(2):226-34. PubMed ID: 21352267
[TBL] [Abstract][Full Text] [Related]
4. Human variability in polymorphic CYP2D6 metabolism: Implications for the risk assessment of chemicals in food and emerging designer drugs.
Darney K; Lautz LS; Béchaux C; Wiecek W; Testai E; Amzal B; Dorne JLCM
Environ Int; 2021 Nov; 156():106760. PubMed ID: 34256299
[TBL] [Abstract][Full Text] [Related]
5. Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I.
Zhou SF
Clin Pharmacokinet; 2009; 48(11):689-723. PubMed ID: 19817501
[TBL] [Abstract][Full Text] [Related]
6. Tolterodine does not affect the human in vivo metabolism of the probe drugs caffeine, debrisoquine and omeprazole.
Brynne N; Böttiger Y; Hallén B; Bertilsson L
Br J Clin Pharmacol; 1999 Feb; 47(2):145-50. PubMed ID: 10190648
[TBL] [Abstract][Full Text] [Related]
7. Influence of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamic of tolterodine.
Brynne N; Dalén P; Alván G; Bertilsson L; Gabrielsson J
Clin Pharmacol Ther; 1998 May; 63(5):529-39. PubMed ID: 9630826
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of venlafaxine extended release 75 mg and desvenlafaxine 50 mg in healthy CYP2D6 extensive and poor metabolizers: a randomized, open-label, two-period, parallel-group, crossover study.
Nichols AI; Focht K; Jiang Q; Preskorn SH; Kane CP
Clin Drug Investig; 2011; 31(3):155-67. PubMed ID: 21288052
[TBL] [Abstract][Full Text] [Related]
9. Effect of ketoconazole on venlafaxine plasma concentrations in extensive and poor metabolisers of debrisoquine.
Lindh JD; Annas A; Meurling L; Dahl ML; AL-Shurbaji A
Eur J Clin Pharmacol; 2003 Sep; 59(5-6):401-6. PubMed ID: 12898080
[TBL] [Abstract][Full Text] [Related]
10. The effects of tramadol on static and dynamic pupillometry in healthy subjects--the relationship between pharmacodynamics, pharmacokinetics and CYP2D6 metaboliser status.
Fliegert F; Kurth B; Göhler K
Eur J Clin Pharmacol; 2005 Jun; 61(4):257-66. PubMed ID: 15906019
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of tolterodine in Japanese and Koreans: physiological and stochastic assessment of ethnic differences.
Oishi M; Chiba K; Malhotra B; Suwa T
Drug Metab Pharmacokinet; 2011 Jun; 26(3):236-41. PubMed ID: 21273733
[TBL] [Abstract][Full Text] [Related]
12. Human variability in glucuronidation in relation to uncertainty factors for risk assessment.
Dorne JL; Walton K; Renwick AG
Food Chem Toxicol; 2001 Dec; 39(12):1153-73. PubMed ID: 11696390
[TBL] [Abstract][Full Text] [Related]
13. Inter-individual variability of in vivo CYP2D6 activity in different genotypes.
Chiba K; Kato M; Ito T; Suwa T; Sugiyama Y
Drug Metab Pharmacokinet; 2012; 27(4):405-13. PubMed ID: 22277677
[TBL] [Abstract][Full Text] [Related]
14. Venlafaxine metabolism as a marker of cytochrome P450 enzyme 2D6 metabolizer status.
Nichols AI; Lobello K; Guico-Pabia CJ; Paul J; Preskorn SH
J Clin Psychopharmacol; 2009 Aug; 29(4):383-6. PubMed ID: 19593180
[TBL] [Abstract][Full Text] [Related]
15. Ketoconazole inhibits the metabolism of tolterodine in subjects with deficient CYP2D6 activity.
Brynne N; Forslund C; Hallén B; Gustafsson LL; Bertilsson L
Br J Clin Pharmacol; 1999 Oct; 48(4):564-72. PubMed ID: 10583027
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic profile of fesoterodine.
Malhotra B; Guan Z; Wood N; Gandelman K
Int J Clin Pharmacol Ther; 2008 Nov; 46(11):556-63. PubMed ID: 19000553
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic and tolerability profile of pridopidine in healthy-volunteer poor and extensive CYP2D6 metabolizers, following single and multiple dosing.
Lindskov Krog P; Osterberg O; Gundorf Drewes P; Rembratt Å; Schultz A; Timmer W
Eur J Drug Metab Pharmacokinet; 2013 Mar; 38(1):43-51. PubMed ID: 22948856
[TBL] [Abstract][Full Text] [Related]
18. Fluoxetine inhibits the metabolism of tolterodine-pharmacokinetic implications and proposed clinical relevance.
Brynne N; Svanström C; Aberg-Wistedt A; Hallén B; Bertilsson L
Br J Clin Pharmacol; 1999 Oct; 48(4):553-63. PubMed ID: 10583026
[TBL] [Abstract][Full Text] [Related]
19. Psychotropic effects of dextromethorphan are altered by the CYP2D6 polymorphism: a pilot study.
Zawertailo LA; Kaplan HL; Busto UE; Tyndale RF; Sellers EM
J Clin Psychopharmacol; 1998 Aug; 18(4):332-7. PubMed ID: 9690700
[TBL] [Abstract][Full Text] [Related]
20. Polymorphic drug metabolism (CYP2D6) and utilisation of psychotropic drugs in hospitalised psychiatric patients: a retrospective study.
Tamminga WJ; Wemer J; Oosterhuis B; de Boer A; Vranckx S; Drenth BF; de Zeeuw RA; de Leij LF; Jonkman JH
Eur J Clin Pharmacol; 2003 May; 59(1):57-64. PubMed ID: 12743673
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
